Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELUT NASDAQ:IMNN NASDAQ:LITS NASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.01+3.6%$1.11$0.50▼$2.64$43.21M0.75195,765 shs118,912 shsIMNNImunon$2.77-0.2%$3.03$2.52▼$41.22$10.84M2.0476,834 shs51,131 shsLITSLite Strategy$1.15+0.4%$1.16$0.95▼$9.00$41.63M0.25336,205 shs197,145 shsMIRAMIRA Pharmaceuticals$1.02-0.5%$1.11$0.90▼$2.45$42.65M1.48154,601 shs71,010 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia-3.40%-2.43%-16.61%-1.66%-48.65%IMNNImunon-1.07%+0.73%-13.98%-11.22%-78.25%LITSLite Strategy+0.88%0.00%+1.79%+7.55%+113,999,900.00%MIRAMIRA Pharmaceuticals-1.92%+0.99%-8.11%-15.70%-12.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.01+3.6%$1.11$0.50▼$2.64$43.21M0.75195,765 shs118,912 shsIMNNImunon$2.77-0.2%$3.03$2.52▼$41.22$10.84M2.0476,834 shs51,131 shsLITSLite Strategy$1.15+0.4%$1.16$0.95▼$9.00$41.63M0.25336,205 shs197,145 shsMIRAMIRA Pharmaceuticals$1.02-0.5%$1.11$0.90▼$2.45$42.65M1.48154,601 shs71,010 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia-3.40%-2.43%-16.61%-1.66%-48.65%IMNNImunon-1.07%+0.73%-13.98%-11.22%-78.25%LITSLite Strategy+0.88%0.00%+1.79%+7.55%+113,999,900.00%MIRAMIRA Pharmaceuticals-1.92%+0.99%-8.11%-15.70%-12.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELUTElutia 2.50Moderate Buy$6.00493.47% UpsideIMNNImunon 2.00Hold$132.504,692.04% UpsideLITSLite Strategy 1.00SellN/AN/AMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest IMNN, ELUT, MIRA, and LITS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$10.004/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/27/2026MIRAMIRA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELUTElutia$12.29M3.52N/AN/A$0.65 per share1.56IMNNImunonN/AN/AN/AN/A$2.30 per shareN/ALITSLite Strategy$65.30M0.64$6.03 per share0.19$4.96 per share0.23MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELUTElutia$53.38M$0.821.23N/AN/A282.63%N/A-49.57%5/14/2026 (Estimated)IMNNImunon-$14.49M-$7.97N/AN/AN/AN/A-406.71%-157.02%5/11/2026 (Estimated)LITSLite Strategy-$15.94M-$1.33N/AN/AN/AN/A-68.86%-67.48%N/AMIRAMIRA Pharmaceuticals-$10.44M-$1.53N/AN/AN/AN/A-210.90%-198.94%6/3/2026 (Estimated)Latest IMNN, ELUT, MIRA, and LITS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ELUTElutia-$0.15N/AN/AN/A$3.00 millionN/A5/11/2026Q1 2026IMNNImunon-$1.2150N/AN/AN/AN/AN/A3/31/2026Q4 2025IMNNImunon-$1.43-$1.29+$0.14-$1.30($0.73) millionN/A3/11/2026Q4 2025ELUTElutia-$0.14-$0.14N/A$1.48$3.30 million$3.30 million2/17/2026Q2 2026LITSLite StrategyN/A-$0.82N/A-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELUTElutiaN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELUTElutiaN/A2.222.12IMNNImunonN/A2.322.32LITSLite StrategyN/A10.0410.04MIRAMIRA PharmaceuticalsN/A15.7515.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELUTElutia74.03%IMNNImunon4.47%LITSLite Strategy52.38%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipELUTElutia27.60%IMNNImunon5.96%LITSLite Strategy1.60%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELUTElutia18042.78 million30.98 millionNot OptionableIMNNImunon303.92 million3.69 millionNot OptionableLITSLite Strategy10036.36 million35.78 millionN/AMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableIMNN, ELUT, MIRA, and LITS HeadlinesRecent News About These CompaniesVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains Traction3 hours ago | newsfilecorp.comNWhat's going on with MIRA Pharma stock Tuesday?March 24, 2026 | msn.comMIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55March 23, 2026 | tipranks.comMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesMarch 23, 2026 | accessnewswire.comAMIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trialMarch 5, 2026 | yahoo.comMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2March 4, 2026 | accessnewswire.comAMIRA Completes Phase 1 Trial of Ketamir-2 TherapyMarch 3, 2026 | tipranks.comWhy MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 13.39%March 3, 2026 | aaii.comAVisionstate Repositions Under MIRA Compliance Platform and Reports Subscription GrowthFebruary 19, 2026 | newsfilecorp.comNMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyFebruary 3, 2026 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final CohortFebruary 2, 2026 | tipranks.comMIRA Pharmaceuticals Expands Stock Offering by $15MDecember 5, 2025 | tipranks.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 83.10% to 3.06October 29, 2025 | msn.comMIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a IndicationOctober 24, 2025 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Clinical TrialsOctober 23, 2025 | tipranks.comMira Pharmaceuticals announces preclinical data on oral Mira-55October 17, 2025 | msn.comMIRA Pharmaceuticals Inc.October 16, 2025 | barrons.comMira Pharmaceuticals stock soars after positive pain treatment study resultsOctober 16, 2025 | za.investing.comMira Pharmaceuticals (MIRA) Stock Rockets After Pain Drug Tops Morphine in TrialsOctober 16, 2025 | blockonomi.comMIRA Pharmaceuticals Sells Shares at 66% PremiumOctober 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026IMNN, ELUT, MIRA, and LITS Company DescriptionsElutia NASDAQ:ELUT$1.01 +0.04 (+3.62%) As of 12:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Imunon NASDAQ:IMNN$2.76 -0.01 (-0.18%) As of 12:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Lite Strategy NASDAQ:LITS$1.14 +0.01 (+0.44%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.01 -0.01 (-0.49%) As of 12:25 PM Eastern This is a fair market value price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
